Questions discussed in this category
Are there specific immunosuppressive agents effective for this manifestation?
For example, is captopril dialyzable?
Would it be safe to resume and if so, when?
Do you prefer to start with nintedanib and then add immunosuppressive agents, or give a trial of immunosuppressive medication first, then add nintedan...
Would you have a different opinion based on whether it is a new therapy or an existing and previously well-tolerated therapy for the patient?
2200522047218392059021540206292105512919990520532200101924817509194401917112645175841644217599161361447910788
Papers discussed in this category
BMJ Open, 2019 May 05
Rheumatol Int, 2021 Jan 29
Scientific reports, 2017 Aug 10
N. Engl. J. Med., 2019 May 20
N Engl J Med, 2019 Sep 29
Arthritis Care Res (Hoboken), 2016 Jan
Alimentary pharmacology & therapeutics, 2022 May 20
Arthritis & rheumatology (Hoboken, N.J.), 2015-05
International journal of rheumatic diseases, 2014-02
Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2014-04-18
Clinical nuclear medicine, 2016-05
J Investig Med High Impact Case Rep, 2021 Jan-Dec
Clinical therapeutics, 2018 Feb
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2015-08-01
Current opinion in pulmonary medicine, 2013 Sep
International journal of cardiology. Heart & vasculature, 2021 Apr 29
Lupus, 2014 Jul 30
MMWR. Morbidity and mortality weekly report, 2024 Sep 12
Journal of the Endocrine Society, 2022 Dec 02
Diagnostics (Basel, Switzerland), 2021 Apr 20
Rheumatology (Oxford),
Rheumatology (Oxford, England), 2023 Dec 01